| NCT07021898 | A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors. | RECRUITING | PHASE1 | 2025-08-06 | 2028-12 | 2028-08 |
| NCT06983743 | A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors | RECRUITING | PHASE1 | 2025-06-05 | 2028-12-01 | 2028-05-01 |
| NCT06346067 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | RECRUITING | PHASE3 | 2024-04-29 | 2028-12 | 2028-04 |
| NCT05907304 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations | ACTIVE_NOT_RECRUITING | PHASE1 | 2023-08-17 | 2025-11 | 2025-07 |
| NCT05279859 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies | WITHDRAWN | PHASE1, PHASE2 | 2022-03-15 | 2025-06-01 | 2025-03-01 |
| NCT05039177 | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2021-09-20 | 2025-12 | 2025-08 |
| NCT04959981 | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC | COMPLETED | PHASE1 | 2021-09-02 | 2023-04-27 | 2023-04-27 |
| NCT04866134 | A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2021-05-07 | 2025-11-01 | 2025-05-01 |
| NCT04670679 | A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors | ACTIVE_NOT_RECRUITING | PHASE1 | 2020-12-15 | 2026-02 | 2025-11 |